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Abstract
Background: This article summarizes the European Renal Association – European Dialysis and Transplant Association
(ERA-EDTA) Registry’s 2015 Annual Report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage
renal disease (ESRD) in 2015 within 36 countries.
Methods: In 2016 and 2017, the ERA-EDTA Registry received data on patients who were undergoing RRT for ESRD in 2015,
from 52 national or regional renal registries. Thirty-two registries provided individual patient-level data and 20 provided
aggregated-level data. The incidence, prevalence and survival probabilities of these patients were determined.
Results: In 2015, 81 373 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 119 per
million population (pmp). The incidence ranged by 10-fold, from 24 pmp in Ukraine to 232 pmp in the Czech Republic.
Of the patients commencing RRT, almost two-thirds were men, over half were aged65 years and a quarter had diabetes
mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 85% of the patients,
peritoneal dialysis for 11% and a kidney transplant for 4%. By Day 91 of commencing RRT, 82% of patients were receiving
haemodialysis, 13% peritoneal dialysis and 5% had a kidney transplant. On 31 December 2015, 546 783 individuals were
receiving RRT for ESRD, corresponding to an unadjusted prevalence of 801 pmp. This ranged throughout Europe by more
than 10-fold, from 178 pmp in Ukraine to 1824 pmp in Portugal. In 2015, 21 056 kidney transplantations were performed,
equating to an overall unadjusted transplant rate of 31 pmp. This varied from 2 pmp in Ukraine to 94 pmp in the Spanish
region of Cantabria. For patients commencing RRT during 2006–10, the 5-year unadjusted patient survival probabilities on
all RRT modalities combined was 50.0% (95% confidence interval 49.9–50.1).
Key words: dialysis, end-stage renal disease, epidemiology, kidney transplantation, survival analysis
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Introduction
The European Renal Association – European Dialysis and
Transplant Association (ERA-EDTA) Registry’s Annual Report
describes the epidemiology of renal replacement therapy (RRT)
for end-stage renal disease (ESRD) within Europe and countries
bordering the Mediterranean Sea based on data collected via
national and regional renal registries [1]. On an annual basis we
publish a summary of the ERA-EDTA Registry’s Annual Report
that is intended to provide an overview of the current status of
RRT for ESRD in Europe [2–4]. In 2016 and 2017, we received the
2015 data from 52 national or regional renal registries in 36
countries covering a general population of 683.4 million people,
representing 80.3% of the 2015 European general population.
Thirty-two national or regional renal registries from 17 coun-
tries provided individual patient data, whereas 20 countries or
Table 1. Incidence of RRT in 2015 at Day 1, for all primary renal diseases combined and diabetes mellitus Types 1 and 2, as count (n) and unad-
justed rate pmp, and the mean age at the start of RRT
Country/region
General population
covered by the registry
in thousands
Incidence of RRT in 2015, at Day 1
All (n) All (pmp) Mean age (years) DM (n) DM (pmp)
Albania 2851 251 88 52.5 30 11
Austria 8585 1204 140 65.0 316 37
Belarus 9299 747 80 167 18
Belgium, Dutch-speakinga 6473 1158 179 70.6 234 36
Belgium, French-speakinga 4802 902 188 67.8 197 41
Bosnia and Herzegovina 3531 404 114 61.4 122 35
Bulgariab 7154 1093 153 278 39
Croatia 3427 540 158 65.3 168 49
Cyprus 855 164 192 66.3 61 71
Czech Republicb 10 293 2393 232
Denmark 5740 621 108 62.3 179 31
Estonia 1315 114 87 58.6 23 17
Finland 5480 520 95 59.6 177 32
France 66 624 11 084 166 67.9 2513 38
Georgia 3714 694 187 61.9 158 43
Greece 10 821 2455 227 69.6 646 60
Iceland 331 24 73 57.4 5 15
Israel 8380 1606 192 65.3 723 86
Italy (5 of 20 regions) 16 986 2232 131 68.2 402 24
Latvia 1574 152 97 62.2 23 15
Lithuania 2921 308 105 64.7 44 15
Macedonia 2022 307 152 63.5 71 35
Norway 5189 514 99 63.0 90 17
Poland 37 967 6617 174
Portugal 10 375 2352 227 771 74
Romania 19 617 3125 159 61.7 355 18
Russia 145 080 7413 51 52.3 1297 9
Serbia 7095 818 115 62.4 185 26
Slovakia 5426 916 169 62.8 334 62
Spain (all regions) 46 624 6277 135 64.8 1454 31
Spain, Andalusia 8402 1037 123 62.6 263 31
Spain, Aragon 1323 155 117 66.2 6 5
Spain, Asturias 1050 176 168 66.6 45 43
Spain, Basque country 2165 265 122 64.8 58 27
Spain, Cantabriaa 584 61 104 65.6 16 27
Spain, Castile and Leo´na 2466 287 116 67.4 71 29
Spain, Castile-La Manchaa 2056 220 107 64.0 47 23
Spain, Catalonia 7508 1247 166 66.9 213 28
Spain, Extremadura 1093 152 139 66.2 34 31
Spain, Galicia 2728 393 144 65.6 104 38
Spain, Community of Madrid 6437 807 125 65.2 217 34
Spain, Region of Murcia 1467 184 125 62.3 37 25
Spain, Navarrea 637 92 144 63.6 16 25
Spain, Valencian region 4981 734 147 64.8 147 30
Sweden 9799 1166 119 63.7 306 31
Switzerland 8282 848 102 64.6 155 19
The Netherlands 16 940 1996 118 63.7 375 22
Tunisia, Sfax region 1186 193 163 59.4 62 52
(continued)
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Table 1. (continued)
Country/region
General population
covered by the registry
in thousands
Incidence of RRT in 2015, at Day 1
All (n) All (pmp) Mean age (years) DM (n) DM (pmp)
Turkeyc 78 736 11 597 147 636 8
Ukraine 42 759 1024 24 48.1 248 6
UK, Englanda,d 54 786 6323 115 62.3 1546 28
UK, Northern Irelanda 1852 220 119 63.5 51 28
UK, Scotland 5373 619 115 59.6 173 32
UK, Walesa 3099 382 123 63.3 104 34
All countries 683 363 81 373 119 63.1 14 679 26
When cells are left empty, the data are unavailable and could not be used for the calculation of the summary data.
aPatients younger than 20 years of age are not reported. The true incidence counts are, therefore, slightly higher than the counts reported here.
bData on incidence include dialysis patients only.
cData on incidence of primary renal disease (DM) is based on 1707 dialysis patients (14.7% of total).
dThe incidence is underestimated by 4% due to a small number of centres not submitting complete data for 2015.
DM , diabetes mellitus as primary renal disease.
Fig. 1. Unadjusted incidence rates of RRT pmp, by country/region at Day 1 in 2015. The incidence rate for Bulgaria, the Czech Republic, Russia and Slovakia only
includes patients receiving dialysis. For England (UK), the overall incidence of RRT is underestimated by 4%.
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regions provided aggregated-level data (see Appendix 1). The
proportion of the European population covered by the ERA-
EDTA Registry in 2015 was higher than in 2014 (65.4%) due to
the inclusion of Russia and Belarus in this year’s Annual Report.
Furthermore, compared with the 2014 ERA-EDTA Registry’s
Annual Report, Switzerland switched from providing aggregated
data to providing individual patient data, while Montenegro
was unable to provide data.
Fig. 2. Unadjusted (left panel) and adjusted (right panel) incidence rates of RRT pmp by country/region at Day 1 in 2015. Registries providing individual patient data are
shown as dark bars, and registries providing aggregated-level data as light bars. Adjustment of incidence rates was performed by standardizing the rates to the age
and gender distribution of the EU27 population [5]. The incidence rate for Bulgaria, the Czech Republic, Russia and Slovakia only includes patients receiving dialysis.
For England (UK), the overall incidence of RRT is underestimated by 4%.
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This summary presents the 2015 incidence and prevalence of
patients receiving RRT, kidney transplantation activity and the
patient and graft survival in these 36 countries. A description of
the methods to analyse the data, along with the full results, can
be found in the ERA-EDTA Registry 2015 Annual Report [1].
Results
Incidence of RRT
In 2015, 81 373 individuals commenced RRT for ESRD, which
equated to an overall unadjusted incidence rate of 119 per mil-
lion population (pmp, Table 1). The unadjusted incidence rate
was highest in the Czech Republic (232 pmp), Greece (227 pmp)
and Portugal (227 pmp), whereas it was lowest in Ukraine (24
pmp) and Russia (51 pmp, Table 1 and Figures 1 and 2). The top
five countries with the highest incident rates were equal to the
top five in 2014, except for the Czech Republic, which had the
fourth highest incident rate in 2014, but the highest incident
rate in 2015. Of the patients commencing RRT, 62% were men,
52% were aged65 years and 23% had diabetes mellitus as their
primary renal diagnosis (Figure 3). The mean age of the patients
commencing RRT in all countries and regions combined was
63.1 years, ranging from 48.1 years in Albania to 70.6 years in the
Dutch-speaking part of Belgium (Table 1). The majority of
patients started RRT with haemodialysis (85%), while 11% of
patients started with peritoneal dialysis and 4% received a pre-
emptive kidney transplant (Figure 4). However, the initial treat-
ment modality varied considerably between age groups, as the
proportion of patients receiving either peritoneal dialysis or a
pre-emptive transplant decreased with increasing age.
Furthermore, patients with a primary renal diagnosis of
Fig. 3. Unadjusted incidence of RRT (%) by (A) gender, (B) age and (C) primary renal diagnosis at Day 1 in 2015. See Appendix 1 for a list of countries and regions supply-
ing individual patient-level or aggregated-level data.
Fig. 4. Unadjusted incidence (%) of (A) treatment modality overall, and treatment modality by (B) gender, (C) age and (D) primary renal diagnosis in 2015. (B–D) Only
based on data from registries providing individual patient data. See Appendix 1 for a list of countries and regions supplying individual patient-level or aggregated-level
data. HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; DM, diabetes mellitus.
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diabetes mellitus were less likely to receive a pre-emptive kid-
ney transplant compared with the non-diabetic group (2% ver-
sus 6%). Of the incident patients alive and receiving RRT at Day
91 after the start of treatment, the majority (82%) were receiving
haemodialysis, 13% were receiving peritoneal dialysis and 5%
were living with a kidney transplant (Figure 5). In the first
90 days of treatment, the percentage of patients receiving hae-
modialysis decreased, this was particularly evident in the
younger age groups.
Prevalence of RRT
On 31 December 2015, 546 783 individuals were receiving RRT
for ESRD (Table 2). This corresponds to an overall unadjusted
prevalence of 801 pmp. Again there was considerable variation
between countries, with the highest unadjusted prevalence
seen in Portugal (1824 pmp) and the Spanish regions of
Catalonia (1355 pmp) and Valencia (1333 pmp) (Table 2 and
Figures 6 and 7). The unadjusted prevalence of RRT was consid-
erably lower in Ukraine (178 pmp) and Russia (303 pmp). The
top five countries with the highest prevalence remained the
same as with 2014. Of the prevalent patients the majority were
men (60%), 42% were aged65 years and 16% had diabetes mel-
litus as their primary renal diagnosis (Figure 8). The mean age
of the prevalent patients receiving RRT in all countries and
regions combined was 60.8 years, ranging from 48.6 years in
Ukraine to 66.8 years in Portugal (Table 2). The majority of prev-
alent patients (58%) were receiving haemodialysis, 36% of
patients were living with a kidney transplant and only 5% were
on peritoneal dialysis (Figure 9). Once again the modality of RRT
varied considerably between age groups as the proportion of
patients with a kidney transplant decreased with increasing
age. For those aged 20–44 years, 66% were living with a kidney
transplant whereas this was true for only 42% of patients aged
65–74 years. Prevalent patients with a primary renal diagnosis
of diabetes mellitus were much less likely to be living with a
kidney transplant compared with the patients without diabetes
mellitus (28% versus 49%).
Kidney transplantation
In 2015, 21 056 kidney transplantations were performed, which
equated to an overall unadjusted transplant rate of 31 pmp
(Figure 10). Again there was considerable variation between
countries/regions with unadjusted kidney transplant rates well
over 70 pmp in some Spanish regions, and very low unadjusted
kidney transplant rates in Ukraine (2 pmp) and Macedonia (6
pmp). Overall, the unadjusted deceased donor transplant rate
was more than twice that of the unadjusted living donor trans-
plant rate (23 pmp versus 10 pmp; 68% versus 29%, Figure 11).
The highest unadjusted rates of deceased donor transplants
were seen in some Spanish regions (>60 pmp, Figure 12),
whereas the highest unadjusted rate of living donor transplants
were seen in the Netherlands (30 pmp), Turkey (32 pmp) and
Northern Ireland (33 pmp, Figure 12).
Survival of patients receiving RRT
For patients commencing RRT in the period 2006–10, the 1-, 2-
and 5-year unadjusted patient survival probabilities for all RRT
modalities combined were 83.2% [95% confidence interval (CI)
83.1–83.4], 72.7% (95% CI 72.6–72.9) and 50.0% (95% CI 49.9–50.1),
respectively (see Table 3 for a description of the countries/
regions included in this analysis). For patients commencing
dialysis between 2006 and 2010, the 5-year unadjusted patient
survival probability was 41.8% (95% CI 41.7–41.9). Adjusted
Fig. 5. Unadjusted incidence (%) of (A) treatment modality overall, and treatment modality by (B) gender, (C) age and (D) primary renal diagnosis at Day 91 in 2015. (B–D)
Only based on data from registries providing individual patient data. See Appendix 1 for a list of countries and regions supplying individual patient-level or aggre-
gated-level data. HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; DM, diabetes mellitus.
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Table 2. Prevalence of RRT on 31 December 2015, for all primary renal diseases combined and diabetes mellitus Types 1 and 2, as count (n) and
unadjusted rate pmp, and the mean age of prevalent patients
Country/region
General population
covered by the registry
in thousands
Prevalent patients on RRT in 2015
All (n) All (pmp) Mean age (years) DM (n) DM (pmp)
Albania 2851 1214 426 50.3 144 51
Austria 8585 9259 1079 61.0 1828 213
Belarus 9299 3204 345 444 48
Belgium, Dutch-speakinga 6473 8142 1258 65.8 1400 216
Belgium, French-speakinga 4802 6143 1279 64.8 1071 223
Bosnia and Herzegovina 3531 2653 751 59.4 512 145
Bulgaria 7154 4241 593
Croatia 3427 2553 745 65.6 656 191
Cyprus 855
Czech Republic 10 293 11 444 1112
Denmark 5740 5190 904 58.4 878 153
Estonia 1315 869 661 57.8 163 124
Finland 5480 4679 854 58.8 1189 217
France 66 624 83 042 1246 63.0 13 217 198
Georgia 3714 2327 627 56.5 483 130
Greece 10 821 13 359 1235 64.0 2485 230
Iceland 331 218 659 54.6 23 70
Israelb 8380 6442 769 65.6 2954 352
Italy (5 of 20 regions) 16 986 17 832 1050 62.2 2061 121
Latvia 1574 1007 640 55.9 95 60
Lithuania 2921 2203 754
Macedonia 2022 1598 790 57.8 245 121
Norway 5189 4836 932 59.3 644 124
Poland 37 967 30 400 801
Portugalc 10 375 18 928 1824 66.8 3392 327
Romaniad 19 617 18 977 967 60.5 1996 102
Russia 145 080 43 955 303 54.4 5318 37
Serbia 7095 5673 800 59.2 935 132
Slovakiab 5426 3337 615 63.3 1145 211
Spain (all regions) 46 624 56 354 1209 63.2 8863 190
Spain, Andalusia 8402 9640 1147 60.2 1476 176
Spain, Aragon 1323 1539 1164 62.7 238 180
Spain, Asturias 1050 1256 1196 62.8 206 196
Spain, Basque country 2165 2656 1227 61.8 286 132
Spain, Cantabriaa 584 662 1134 62.2 89 152
Spain, Castile and Leo´na 2466 2761 1119 64.3 476 193
Spain, Castile-La Manchaa 2056 2241 1090 62.0 341 166
Spain, Catalonia 7508 10 171 1355 62.7 1414 188
Spain, Community of Madrid 6437 7008 1089 61.5 1247 194
Spain, Extremadura 1093 1256 1149 61.4 191 175
Spain, Galicia 2728 3559 1305 62.2 608 223
Spain, Navarrea 637 799 1254 62.0 112 176
Spain, Region of Murcia 1467 1888 1287 61.8 257 175
Spain, Valencian region 4981 6638 1333 62.8 883 177
Sweden 9799 9421 961 59.6 1668 170
Switzerlande 8282 7714 931 62.5 1166 141
The Netherlands 16 940 16 764 990 60.1 2122 125
Tunisia, Sfax regionb 1186 923 778 58.3 184 155
Turkeyf 78 736 73 660 936 2048 26
UK, Englanda,g 54 786 50 999 931 58.6 8483 155
UK, Northern Irelanda 1852 1693 914 58.4 258 139
UK, Scotland 5373 4923 916 56.6 781 145
UK, Walesa 3099 2997 967 59.4 509 164
Ukraine 42 759 7610 178 48.6 1137 27
All countries 683 363 546 783 801 60.8 70 497 128
When cells are left empty, the data are unavailable and could not be used for the calculation of the summary data.
aPatients younger than 20 years of age are not reported. The true prevalent counts are therefore slightly higher than the counts reported here.
bData on prevalence include dialysis patients only.
cData on prevalence of primary renal disease (DM) include dialysis patients only.
dThe prevalence is underestimated by 3% due to an estimated 30% underreporting of patients living on a functioning graft.
eThe prevalence is underestimated by 6% due to an estimated 11% underreporting of patients living on a functioning graft.
fData on the prevalence of primary renal disease (DM) is based on 6400 dialysis patients (8.7% of total).
gThe prevalence is underestimated by 1% due to a small number of centres not submitting complete data for 2015.
DM, diabetes mellitus as primary renal disease.
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analyses comparing patient survival on haemodialysis and peri-
toneal dialysis revealed higher survival probabilities in the first
3 years for patients on peritoneal dialysis (Figure 13). For those
with a kidney transplant, 5-year adjusted patient and graft
survival were higher with a living donor transplant compared
with a deceased donor transplant [94.5% (95% CI 94.0–95.0) ver-
sus 91.7% (95% CI 91.3–92.1) for patient survival and 86.6% (95%
CI 85.8–87.4) versus 80.7% (95% CI 80.2–81.2) for graft survival].
Fig. 6. Unadjusted prevalence of RRT pmp by country/region on 31 December 2015. The prevalence for Israel, Slovakia and Tunisia (Sfax region) only includes patients
receiving dialysis. For Romania, Switzerland and England (UK), the overall prevalence of RRT is underestimated by, respectively, 3, 6 and 1%.
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See Table 3 for a description of the adjustments made and the
countries/regions included in this analysis.
Expected remaining lifetime
There remains a substantial difference in the expected remaining
lifetime between the general population and those receiving dialysis
(Figure 14). Patients aged 20–44 years receiving dialysis are expected
to live only one-third of the estimated remaining lifetime of the
age-matched general population, which is about 35 years less. The
prospect is even worse for patients aged 55–64 years, as they are
expected to live only a quarter as long as their age-matched coun-
terparts in the general population (20 years less). Patients living
with a kidney transplant fare better than those receiving dialysis.
Fig. 7. Unadjusted (left panel) and adjusted (right panel) prevalence of RRT pmp by country/region on 31 December 2015. Registries providing individual patient data
are shown as dark bars, and registries providing aggregated-level data as light bars. Adjustment of the prevalence was performed by standardizing the prevalence to
the age and gender distribution of the EU27 population [5]. The prevalence for Israel, Slovakia and Tunisia (Sfax region) only includes patients receiving dialysis. For
Romania, Switzerland and England (UK), the overall prevalence of RRT is underestimated by, respectively, 3, 6 and 1%.
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However, the life expectancy of the transplant recipients aged 20–
44 years is still approximately one-third less than that of the age-
matched general population (17 years less). With increasing age of
transplant recipients the percentage disparity in life expectancy
with the age-matched general population also increases.
Affiliated registries
Albanian Renal Registry (M. Barbullushi, A. Idrizi and E. Bolleku
Likaj); Austrian Dialysis and Transplant Registry (OEDTR) (R.
Kramar); Belarus Renal Registry (K. S. Komissarov, A. V.
Kalachyk and O. V. Krasko); Dutch-speaking Belgian Society of
Nephrology (NBVN) (B. De Moor, F. Schroven and J. De Meester);
French-speaking Belgian Society of Nephrology (GNFB) (J. M. des
Grottes and F. Collart); Renal Registry Bosnia and Herzegovina
(H. Resic, M. Grujicic and S. Coric); Bulgaria (E. S. Vazelov, I.
Velinova and M. Gitcheva); Croatian Registry of Renal
Replacement Therapy (CRRRT) (I. Bubic, S. Racki and N.
Jankovic); Cyprus Renal Registry (K. Ioannou and all of the renal
units providing data); Czech Republic: Registry of Dialysis
Patients (RDP) (I. Rychlı´k, J. Potucek and F. Lopot); Danish
Nephrology Registry (DNS) (J. G. Heaf); Estonian Society of
Nephrology (U¨. Pechter, M. Rosenberg and K. Lilienthal); Finnish
Registry for Kidney Diseases (P. Finne, A. Pylsy and P. H. Groop);
France: The Epidemiology and Information Network in
Nephrology (REIN) (M. Lassalle and C. Couchoud); Georgian
Renal Registry (N. Kantaria and Dialysis Nephrology and
Transplantation Union of Georgia); Hellenic Renal Registry (N.
Afentakis); Icelandic End-Stage Renal Disease Registry (R.
Palsson); Israel National Registry of Renal Replacement Therapy
(R. Dichtiar, T. Shohat and E. Golan); Italian Registry of Dialysis
and Transplantation (RIDT): (A. Limido, M. Nordio and M.
Fig. 8. Unadjusted prevalence (%) by (A) gender, (B) age and (C) primary renal diagnosis on 31 December 2015. See Appendix 1 for a list of countries and regions supply-
ing individual patient-level or aggregated-level data.
Fig. 9. Unadjusted prevalence (%) of (A) treatment modality overall, and treatment modality by (B) gender, (C) age and (D) primary renal diagnosis on 31 December 2015.
(B–D) Only based on data from registries providing individual patient data. See Appendix 1 for a list of countries and regions supplying individual patient-level or aggre-
gated-level data. HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; DM, diabetes mellitus.
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Fig. 10. Kidney transplants performed in 2015, as counts and pmp (unadjusted) by country/region. Registries providing individual patient-level data are shown as dark
bars, and registries providing aggregated-level data as light bars. Data based on patients aged 20 years in Dutch-speaking Belgium, French-speaking Belgium, the
Spanish regions of Cantabria, Castile and Leo´n, Castile-La Mancha and Navarre and the UK: England, Northern Ireland and Wales. The total count for Austria is based
on residents and non-residents. For Romania, Switzerland and England (UK), the overall transplant rate is underestimated by, respectively, 30, 6 and 7%.
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Postorino); Latvian Renal Registry (H. Cernevskis, V. Kuzema
and A. Silda); Lithuanian Renal Registry (V. Kuzminskis, I. A.
Bumblyt _e and E. Ziginskien _e); Macedonian Renal Registry (L.
Trpenovski, J. Masin Spasovska and O. Stojceva-Taneva);
Norwegian Renal Registry (T. Leivestad, A. V. Reisæter and A.
A˚sberg); Polish Renal Registry (M. Klinger, B. Rutkowski and A.
De˛bska-Slizien); Portuguese Renal Registry (F. Maca´rio and A.
Ferreira); Romanian Renal Registry (RRR) (G. Mircescu, L.
Garneata and E. Podgoreanu); Russian Renal Regiostry (N.
Tomilina, A. Andrusev and H. Zakharova); Renal Registry in
Serbia (N. Maksimovic, all of the Serbian renal units and Serbian
Society of Nephrology); Slovakian Renal Registry (V. Spustova´, I.
Lajdova´ and M. Karolyova); Spanish RRT National Registry at
ONT, Spanish Regional Registries and Spanish Society of
Nephrology (SEN) and the regional registries of Andalusia
(SICATA) (P. Castro de la Nuez (on behalf of all users of SICATA),
Aragon (J. I. Sanchez Miret and J. M. Abad Diez), Asturias (R.
Alonso de la Torre, J. R. Quiro´s and RERCA Working Group),
Basque country (UNIPAR) (A´. Magaz, J. Aranzabal, M. Rodrigo
and I. Moina), Cantabria (A. L. M. de Francisco, O. Garcia Ruiz
and C. Pi~nera Haces), Castile and Leo´n (R. Gonza´lez and
Fig. 12. Unadjusted deceased donor (left panel) and living donor (right panel) kidney transplants performed in 2015 pmp, by country/region. Registries providing indi-
vidual patient-level data are shown as dark bars, and registries providing aggregated-level data as light bars. Data based on patients aged 20 years in Dutch-speaking
Belgium, French-speaking Belgium, the Spanish regions of Cantabria, Castile and Leo´n, Castile-La Mancha and Navarre and the UK: England, Northern Ireland and
Wales. The total count for Austria is based on residents and non-residents. For Romania, Switzerland and England (UK), the overall transplant rate is underestimated
by, respectively, 30, 6 and 7%.
Fig. 11. Percentage of kidney transplants performed in 2015 by kidney donor
type. See Appendix 1 for a list of countries and regions supplying individual
patient-level or aggregated-level data.
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Table 3. The survival probabilities at 1, 2 and 5 years by treatment modality and cohort, from Day 1 of the start of RRT/dialysis, or from the day
of kidney transplantation
Survival type
Survival probabilities as percentage (95% CIs)
Cohort: 2006–10 Cohort: 2009–13
1 year 2 years 5 years 1 year 2 years
Patient survival on RRT
Unadjusted 83.2 (83.1–83.4) 72.7 (72.6–72.9) 50.0 (49.9–50.1) 84.4 (84.2–84.5) 74.3 (74.2–74.5)
Adjusteda 85.9 (85.8–86.1) 76.1 (75.9–76.3) 51.1 (50.8–51.4) 86.9 (86.7–87.1) 77.6 (77.4–77.9)
Patient survival on dialysis
Unadjusted 82.2 (82.1–82.4) 70.4 (70.2–70.6) 41.8 (41.7–41.9) 83.3 (83.1–83.4) 71.9 (71.7–72.0)
Adjusteda 84.4 (84.2–84.6) 73.5 (73.3–73.7) 45.0 (44.7–45.4) 85.7 (85.5–85.9) 75.4 (75.2–75.6)
Patient survival after first kidney transplantation (deceased donor)
Unadjusted 96.1 (95.9–96.4) 94.3 (94.1–94.6) 88.0 (87.6–88.3) 96.3 (96.1–96.5) 94.3 (94.0–94.5)
Adjustedb 97.5 (97.3–97.6) 96.2 (96.0–96.4) 91.7 (91.3–92.1) 97.8 (97.7–98.0) 96.5 (96.3–96.7)
Graft survival after first kidney transplantation (deceased donor)
Unadjusted 90.9 (90.5–91.2) 88.1 (87.8–88.5) 78.9 (78.5–79.3) 91.1 (90.8–91.3) 88.1 (87.7–88.4)
Adjustedb 91.8 (91.4–92.1) 89.3 (88.9–89.7) 80.7 (80.2–81.2) 92.4 (92.1–92.7) 89.8 (89.4–90.1)
Patient survival after first kidney transplantation (living donor)
Unadjusted 98.6 (98.3–98.8) 97.7 (97.4–98.0) 94.1 (93.6–94.6) 98.9 (98.7–99.1) 97.9 (97.6–98.2)
Adjustedb 98.7 (98.5–99.0) 98.0 (97.7–98.3) 94.5 (94.0–95.0) 99.1 (98.9–99.2) 98.2 (98.0–98.5)
Graft survival after first kidney transplantation (living donor)
Unadjusted 95.9 (95.4–96.3) 94.1 (93.6–94.5) 87.4 (86.7–88.0) 96.5 (96.2–96.8) 94.7 (94.3–95.1)
Adjustedb 95.6 (95.2–96.1) 93.8 (93.2–94.3) 86.6 (85.8–87.4) 96.3 (95.9–96.7) 94.4 (93.9–94.9)
This is based on data from the following renal registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark,
Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and Leo´n), Spain
(Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Valencian region), Sweden, the Netherlands, UK (all
countries).
aAnalyses were adjusted using fixed values: age (67 years), gender (63% men) and primary renal disease (24% diabetes mellitus, 19% hypertension/renal vascular dis-
ease, 11% glomerulonephritis and 46% other causes).
bAnalyses were adjusted using fixed values: age (50 years), gender (63% men) and primary renal disease (14% diabetes mellitus, 10% hypertension/renal vascular dis-
ease, 23% glomerulonephritis and 53% other causes).
Fig. 13. Adjusted patient survival of patients starting haemodialysis and peritoneal dialysis between 2006 and 2010 from Day 91 (left panel) and patients receiving a first
transplant from a living or deceased donor between 2006 and 2010 (right panel), adjusted for age, gender and primary renal diagnosis. Survival on dialysis was adjusted
using the following fixed values: age (67 years), gender (63% men) and primary renal disease (24% diabetes mellitus, 19% hypertension/renal vascular disease, 11% glo-
merulonephritis and 46% other causes). Survival after kidney transplantation was adjusted using the following fixed values: age (50 years), gender (63% men) and pri-
mary renal disease (14% diabetes mellitus, 10% hypertension/renal vascular disease, 23% glomerulonephritis and 53% other causes). These figures are based on data
from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, France, Greece,
Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and Leo´n), Spain (Castile-La Mancha),
Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Valencian region), Sweden, the Netherlands and UK (all countries).
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C. Ferna´ndez-Renedo), Castile-La Mancha (G. Gutie´rrez A´vila
and I. Moreno Alı´a), Catalonia (RMRC) (E. Arcos, J. Comas and J.
Tort), Extremadura (J. M. Ramos Aceitero and M. A. Garcı´a
Bazaga), Galicia (E. Bouzas-Caama~no and J. Sa´nchez-Iba´~nez),
Community of Madrid (M. I. Aparicio de Madre), Renal Registry
of the Region of Murcia (C. Santiuste de Pablos and I. Marı´n
Sa´nchez), Navarre (M. F. Slon Roblero, J. Manrique Escola and J.
Arteaga Coloma) and the Valencian region (REMRENAL) (M. Ferrer
Alamar, N. Fuster Camarena and J. Pe´rez Penade´s); Swedish
Renal Registry (SNR) (K. G. Pru¨tz, M. Stendahl, M. Evans, S. Scho¨n,
T. Lundgren and M. Segelmark); Swiss Dialysis Registry (P.
Ambu¨hl and R. Winzeler); Dutch Renal Registry (RENINE) (L.
Heuveling, S. Vogelaar and M. Hemmelder); Tunisia, Sfax region
(D. Zalila, H. Mahfoud and F. Jarraya); Registry of the Nephrology,
Dialysis and Transplantation in Turkey (TSNNR) (G. Su¨leymanlar,
N. Seyahi and K. Ates¸); Ukrainian Renal Data System (URDS) (M.
Kolesnyk, S. Nikolaenko and O. Razvazhaieva); United Kingdom
Renal Registry (UKRR) (all the staff of the UK Renal Registry and
of the renal units submitting data); Scottish Renal Registry (SRR)
(all of the Scottish renal units).
ERA-EDTA Registry Committee Members
C. Zoccali, Italy (ERA-EDTA President); Z. A. Massy, France
(Chairman); F. J. Caskey, UK; C. Couchoud, France; M. Evans,
Sweden; P. Finne, Finland; J. W. Groothoff, The Netherlands; J.
Harambat, France; J. G. Heaf, Denmark; F. Jarraya, Tunisia; M.
Nordio, Italy; and I. Rychlik, Czech Republic.
ERA-EDTA Registry Office Staff
K. J. Jager (Managing Director), M. Bonthuis (for the paediatric
section), R. Cornet, G. Guggenheim, A. Kramer, M. Noordzij, M.
Pippias, V. S. Stel and A. J. Weerstra.
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Appendix 1
Countries or regions providing individual
patient-level data
Austria, Dutch-speaking Belgium, French-speaking Belgium,
Bosnia and Herzegovina, Denmark, Estonia, Finland, France,
Greece, Iceland, Norway, Romania, Serbia, the Spanish regions
of Andalusia, Aragon, Asturias, Basque country, Cantabria,
Castile and Leo´n, Castile-La Mancha, Catalonia, Extremadura,
Galicia, Community of Madrid, Murcia, Navarre, Valencian
region, Sweden, Switzerland, the Netherlands, UK (England/
Northern Ireland/Wales) and UK (Scotland).
Countries or regions providing aggregated-
level data
Albania, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic, Georgia,
Israel, Italy, Latvia, Lithuania, Macedonia, Poland, Portugal, Russia,
Slovakia, Spain, Tunisia (Sfax region), Turkey, Ukraine.
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